Is Serratiopeptidase a Placebo Treatment for the Chronic Pain at the Vaccination Site Following MR Vaccination?

Ashok Pandey^1, and Arya Gautam²

¹Medical Officer Urban Health Promotion Centre, Butwal, Nepal

²Intern Universal College of Medical Sciences, Nepal

Cite this paper:
Ashok Pandey and Arya Gautam. Is Serratiopeptidase a Placebo Treatment for the Chronic Pain at the Vaccination Site Following MR Vaccination?. American Journal of Medical Case Reports. 2024; 12(6):91-92. doi: 10.12691/ajmcr-12-6-3

Abstract

Background: Serratiopeptidase is an enzymatic drug that has anti-inflammatory and analgesic effects. Chronic pain at the site of vaccination is considered as an AEFI. In this report, we discuss a case of a 16-year-old female with chronic pain following vaccination and use of serratiopeptidase as an analgesic for her symptoms. Case Presentation: A 16-year-old female came to the primary health care center with pain in the left arm (over the deltoid region) followed by MR vaccination. On examination, there were no any neuromuscular deficits. Her pain was graded 6/10 according to the Numerical Rating Scale for pain. She was given serratiopeptidase for 10 days, which led to the resolution of her symptoms. Conclusion: Here, the case of chronic pain followed by vaccination is presented where the patient was prescribed with serratiopeptidase following failure to resolve her symptoms by other means. Despite the lack of any solid clinical evidence supporting its usage, patient outcome questions whether it is actually a potent analgesic or a placebo drug.

Keywords:
Adverse event following immunization Chronic pain Measles-Rubella Vaccination Serratiopeptidase Analgesic

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Bhagat S, Agarwal M, Roy V. Serratiopeptidase: a systematic review of the existing evidence. Int J Surg. 2013; 11(3): 209-217. [PubMed 23380245].
[2]	D'Souza RM, Campbell-Lloyd S, Isaacs D, et al. Adverse events following immunization associated with the 1998 Australian Measles Control Campaign. Commun Dis Intell. 2000; 24(2): 27-33.
[3]	Chiarotto A, Maxwell LJ, Ostelo RW, et al. Measurement Properties of Visual Analog Scale, Numeric Rating Scale, and Pain Severity Subscale of the Brief Pain Inventory in Patients With Low Back Pain: A Systematic Review. J Pain. 2019; 20(3): 245-263.
[4]	John J. Grading of muscle power: comparison of MRC and analog scales by physiotherapists. Medical Research Council. Int J Rehabil Res. 1984; 7(2): 173-81.
[5]	Mazzone A, Catalani M, Costanzo M, Drusian A, Mandoli A, Russo S, et al. Evaluation of Serratia-peptidase in acute or chronic inflammation of otorhinolaryngology pathology: a multicenter, double-blind, randomized trial versus placebo. J Int Med Res 1990; 18: 379e88.